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Abstract 
Purpose: To investigate the effects of coagulation factors and inflammatory cytokines on acute 
myocardial infarction (AMI) development in patients younger than 60 years.  
Methods: In this study, 60 patients admitted to The First Affiliated Hospital of Dalian Medical University 
(Dalian, China) with AMI and 30 other subjects matched with the patients for age and ethnicity but 
without AMI were enrolled. Blood samples were collected from the AMI patients and the control subjects 
after a 12-h fast. Subsequently, the levels of coagulation factors (F) II (FII), VII (FVII), VIII (FVIII), 
fibrinogen (Fg) and von Willebrand factor (vWF) in plasma were analyzed by enzyme-linked 
immunosorbent assay (ELISA). The protein expression levels of these coagulation factors were 
determined by Western blot analysis. Inflammatory factors including C-reactive protein (CRP), tumor 
necrosis factor-α (TNF-α) and interleukin- 6 (IL-6) were also measured by ELISA. 
Results: FII, FVII, FVIII, Fg and vWF levels in plasm were significantly higher in AMI patients compared 
with control subjects (p < 0.01). Furthermore, the protein expression levels of FII, FVII, FVIII, Fg and 
vWF were also significantly up-regulated in AMI patients compared with those in control subjects. 
Additionally, no significant difference was observed in CRP between AMI patients and control subjects 
(p > 0.05). However, TNF-α and IL-6 levels in the plasma of AMI patients were significantly higher than 
those in control subjects (p < 0.05). 
Conclusion: The results reveal that the pathogenesis of AMI in patients younger than 60 years might 
be closely related to the high levels of coagulation factors and inflammatory cytokines in the blood. 
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Currently, coronary heart disease (CHD) has 
become one of the leading global threats to 
human health [1]. Acute myocardial infarction 
(AMI) is the major clinical complication of CHD 
and the main cause of mortality in patients [2]. 
Although great improvements have been 
achieved in the diagnosis and treatment of AMI, 
the short- and long-term mortality rates in AMI 
patients still remain high [3,4]. In addition, the 
onset age of AMI is becoming increasingly low 
[5,6]. Therefore, it is of great significance to 
investigate the pathogenesis of AMI in patients 
younger than 60 years. 
 
Epidemiological studies have revealed that some 
coagulation factors including coagulation factor 
Wang & Fang 
Trop J Pharm Res, April 2016; 15(4): 828  
 
(F) II (FII), VII (FVII), VIII (FVIII), fibrinogen (Fg) 
and von Willebrand factor (vWF), are closely 
related to thrombus formation and CHD [7,8]. In 
addition, the systemic inflammation response has 
been documented in patients with AMI, and 
includes the elevation of circulating inflammatory 
cytokines such as C-reactive protein (CRP), 
tumor necrosis factor-α (TNF-α), and interleukin- 
6 (IL-6) [9,10]. However, to the best of our 
knowledge, there are few reports regarding the 
effects of coagulation factors and inflammatory 
cytokines on the occurrence and development of 
AMI in patients younger than 60 years. The 
present study was aimed to investigate the 
effects of coagulation factors and inflammatory 
cytokines on the development of acute 
myocardial infarction in patients younger than 60 
years, findings that would be beneficial for the 
accurate diagnosis and effective treatment of 




Chemicals and reagents 
 
Human anti-prothrombin (FII), anti-FVII, anti-
FVIII, anti-Fg and anti-vWF monoclonal 
antibodies were obtained from Abcam 
(Cambridge, UK); CRP, TNF-α and IL-6 ELISA 
kits were purchased from Pierce/Endogen Co. 
(Rockford, IL, USA). FII, FVII, FVIII, Fg and vWF 
enzyme-linked immunosorbent assay (ELSA) kits 
were purchased from Pierce/Endogen Co. 
(Rockford, IL, USA). All other reagents used in 
this study were of analytic grade. 
 
Patients and controls 
 
Sixty patients (39 males and 21 females) 
admitted to The First Affiliated Hospital of Dalian 
Medical University (Dalian, China) with a 
diagnosis of AMI, defined according to the 
guidelines of the WHO MONICA protocol [11], 
were studied. A group of 30 control subjects (19 
males and 11 females) matched with the patients 
for age and ethnicity, were also enrolled in the 
present investigation. No control subject had 
episodes of cardiovascular disease and none 
used antihypertensive or lipid-lowering drugs. 
The characteristics of AMI patients and controls 
are shown in Table 1, and no obvious difference 
of the characteristics was observed between the 
two groups.  
 
Venous blood samples were collected from the 
patients during hospitalization and the control 
subjects after a 12-h fast. Subsequently, 3.8 % 
sodium citrate solution (1:9, v/v) was added to 
the blood, and the samples were centrifuged 
(3000 rpm, 15 min). The isolated plasma was 
snap-frozen and stored at -80 °C before 
measurement. All our experimental protocols 
were approved by the ethical committee of The 
First Affiliated Hospital of Dalian Medical 
University (Ref no. 20120918-h1). All the patients 
and controls were residents of the region of 
Dalian and gave their consent to participate in 
the study. 
 
Table 1: Baseline demographics and disease 
characteristics of AMI patients and control subjects 
 
Variable Control AMI 
Sex (M/F) 19/11 39/21 
Body Weight (kg) 53.73 ± 4.97 51.85 ± 6.16 
Age 54.74± 5.05 52.03 ± 7.21 
Smoking (%) 60 51.67 
Hypertension (%) 46.7 50 
Diabetes (%) 6.7 10 
TC (mmmol/L) 3.48 ± 0.82 3.69 ± 0.98 
TG (mmmol/L) 1.82 ± 0.63 2.08 ± 0.73 
Blood sugar 
(mmmol/L) 5.21 ± 1.14 6.03 ± 1.96 
 
Determination of FII, FVII, FVIII, Fg and vWF 
levels in plasma 
 
Coagulation factors including FII, FVII, VIII 
(FVIII), Fg and vWF in the plasma were analyzed 
by enzyme linked immunosorbent assay (ELISA) 
according to the manufacturer’s instructions. 
 
Determination of FII, FVII, FVIII, Fg and vWF 
protein levels  
 
Total protein samples were separated by sodium 
dodecyl sulfate/polyacrylamide gel 
electrophoresis (SDS/PAGE) and then 
transferred to a polyvinylidene difluoride (PVDF) 
membrane. The proteins were probed with the 
appropriate primary antibodies and secondary 
antibodies conjugated with horseradish 
peroxidase subsequently. Next, they were 
visualized using chemiluminescence peroxidase 
reagents. To normalize the protein loading, β-
actin was used as the internal control.  
 
Determination of CRP, TNF-α and IL-6 levels 
in plasma 
 
Furthermore, inflammatory cytokines including 
CRP, TNF-α and IL-6 were also determined by 





Data are expressed as mean ± standard 
deviation (SD). Student’s t-test was used to 
perform statistical analysis of the data. 
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Differences were considered statistically 




Levels of coagulation factors in plasma  
 
As seen in Figure 1, the ELISA results indicate 
that the plasma levels of coagulation factors, 
including FII, FVII, FVIII, Fg and vWF, were 
significantly higher in AMI patients than in control 
subjects (p < 0.01). Furthermore, the western 
blot assay results also revealed protein 
expression levels of FII, FVII, FVIII, Fg and vWF 
were up-regulated obviously in AMI patients 
compared with those in the control subjects 
(Figure 2). 
 
CRP, TNF-α and IL-6 levels in plasma  
 
The plasma levels of inflammatory factors 
including CRP, TNF-α and IL-6 are shown in 
Figure 3. Our results showed that there were no 
significant differences in the release of CRP 
between AMI patients and the control subjects (p 
> 0.05). Interestingly, the TNF-α and IL-6 levels 
in the plasma of AMI patients were significantly 
higher than those of control subjects (p < 0.05). 
Our results showed that the release of 
inflammatory cytokines, including TNF-α and IL-
6, is associated with pathogenesis of AMI 
patients younger than 60 years. 
 
 
Figure 1: FII, FVII, FVIII, Fg and vWF levels in plasma. Data are expressed as mean ± SD (p < 0.01), compared 
with control group 
 
 
 Figure 2: Protein expressions FII, FVII, FVIII, Fg and vWF in plasma of AMI patients 
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Recently, it had been reported that the AMI) is a 
frequent cause of death or severe permanent 
disability, and the age of AMI patients is 
becoming increasingly young [12,13]. Thus, the 
present study was designed to investigate the 
possible pathogenic mechanism of AMI in 
patients younger than 60 years related to 
coagulation factors and inflammatory cytokines. 
  
AMI is associated with the coagulation and 
thrombotic occlusion of coronary vessels in the 
presence of unstable atheroma [14]. FII, FVII, 
FVIII, Fg and vWF are important coagulation 
factors in the blood coagulation process. FII 
(Prothrombin) plays a central role in the 
coagulation mechanism, and it can be activated 
to FIIa (thrombin). Fg could then change into 
fibrin due to the activation of FIIa [15]. FVII is the 
initiation factor of the exogenous coagulation 
pathway, and its abnormalities in the plasma may 
increase the risk of myocardial infarction and 
sudden death [16]. FVIII is involved in the second 
stage of the coagulation process, and it is also 
involved in the activation of coagulation factor X 
(FX). In addition, vWF and FVII could form a 
complex to stabilize and protect the activity of 
FVIII [17]. Several literature sources have proved 
that these coagulation factors play important 
roles in the development of vascular disease and 
AMI [18-21]. Therefore, we evaluated the plasma 
levels of coagulation factors in AMI patients and 
control subjects. Our results indicate that the 
high levels of coagulation factors in plasma (FII, 
FVII, FVIII, Fg and vWF) were closely related to 
the development of AMI in patients younger than 
60 years. 
 
Increasing investigations have demonstrated that 
inflammation plays an important role in the 
pathogenesis of CHD. Inflammatory cytokines 
including CRP, TNF-α and IL-6 mediate adverse 
cardiovascular events in patients with CHD and 
they are used as indices for diagnosing CHD 
[22,23]. In our present study, the levels of 
inflammatory cytokines, including CRP, TNF-α 
and IL-6, in plasma were determined. Our results 
showed that the levels of TNF-α and IL-6 in AMI 
patients were higher than those control subjects, 
indicating that high levels of TNF-α and IL-6 
might be related to the development of AMI in 




Findings from this study reveal that the 
pathogenesis of AMI in patients younger than 60 
years might be closely related to the high levels 
of coagulation factors and inflammatory 
cytokines in the blood. In addition, the results of 
the present study would be beneficial for 
accurate diagnosis and effective treatment of 
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